BMS-Tempus, Roche-Zymeworks, and LGM-Sannova deals show what AI data, trispecifics, and nitrosamine testing mean for CMC, QA, and development teams.
News|Articles|April 2, 2018
Jim Miller Presents Contract Services Keynote at CPhI North America 2018
Author(s)Pharmaceutical Technology Editors
Industry analyst Jim Miller will provide insight into the past, present, and future of the contract services market at the CPhI North America conference on Wednesday, April 25, 2018 in Philadelphia, PA.
Advertisement
Jim Miller, veteran industry analyst and founder/former president of PharmSource, a GlobalData company, will explore 20-years’ worth of changes in the contract services market during his keynote address
Moderated by Rita Peters, editorial director at Pharmaceutical Technology, the presentation will also cover the impact of recent shifts in the pharma development, manufacturing, distribution, and regulatory landscape on both bio/pharma companies and contract service providers.
For more information, please visit
Source:
Advertisement
Related to this article
Jane Zhang of ETCH Sourcing explains why geopolitics, transparency, and partnership now weigh as heavily as cost and quality when companies choose suppliers, in this episode of Ask the Expert, moderated by Susan J. Schniepp of Nelson Labs.
The PharmTech team focused on its coverage of AAPS PharmSci 360 this week, conducting interviews with experts on a range of topics including formulation platforms, AI, amorphous solid dispersions, and animal studies.
Subathra Ramamoorthy, Veranova, on when to escalate to structural elucidation and pair orthogonal techniques when characterizing an impurity.
Manish Baviskar, Hubot CDMO, on ALCOA++ data integrity, model version change control, continuous monitoring, and human sign-off.
The agreement between CDER and OII with allow for coordinated marketing application assessments and inspections.
Manish Baviskar, Hubot CDMO, explains which AI skills validation engineers need first and why AI model updates must go through GMP change control.
Ron Filler, Drug Development Consultants, explains how USP's 1074 revision brings human-relevant safety science to formulators and excipient makers.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Why AI Model Updates Need Change Control: AAPS PharmSci 360 2026
2
From URS to Acceptance Evidence: Defining and Testing Interfaces in Pen Injector Assembly
3
USP 1074 Revises Excipient Safety: AAPS PharmSci 360 2026
4
AI Formulation: Regulators Want Data
5